Previous 10 | Next 10 |
2019 hasn't been a great year so far for United Therapeutics (NASDAQ: UTHR) . The pharmaceutical stock was down 20% heading into the company's third-quarter update. But United Therapeutics announced its third-quarter results before the market opened on Wednesday, spurring a nice ju...
United Therapeutics ( UTHR ) Q3 results : Revenues: $401.5M (-2.7%). More news on: United Therapeutics Corporation, Healthcare stocks news, Earnings news and commentary, Read more ...
United Therapeutics (NASDAQ: UTHR ): Q3 Non-GAAP EPS of $3.83 beats by $0.93 ; GAAP EPS of $3.01 beats by $0.57 . More news on: United Therapeutics Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 30, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended September 30, 2019. "We are pleased to see continued growth during the quarter in...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 23, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2019 financial results before the market opens on Wednesday, October 30, 2019 . United Therape...
Translate Bio ( TBIO ) has a major catalyst that is approaching towards the end of October of 2019. This will be both an oral and poster presentation of phase 1/2 study data from about 12 patients with cystic fibrosis ((CF)). These results will be presented on November 1, 2019, at the 33rd...
The FDA has approved United Therapeutics' (NASDAQ: UTHR ) supplement to the NDA for Orenitram (treprostinil) Extended-Release Tablets reflecting data from the FREEDOM-EV study in patients with pulmonary arterial hypertension (PAH). More news on: United Therapeutics Corporation, Heal...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 21, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the New Drug Application for Orenitram® (treprostini...
On M arch 1, 2018, MannKind (MNKD) released a PR announcing the start of a Phase 1 clinical trial with their PAH candidate. This study was to determine the safety, tolerability and pharmacokinetics for the Tre-t drug. Thereafter, on June 7 th , 2018, the company announced the Phase 1 c...
2019 has not been kind to United Therapeutic's ( UTHR ) share price so far; the price has collapsed from a high of $125, to $78.54 at the time of writing. Source: TradingView The slump is mainly due to the expiry, or impending expiry of its exclusivity patents for key drug Adcirca, as w...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...